Differences between self-reported and electronically monitored adherence among patients receiving antiretroviral therapy in a resource-limited setting

AIDS

Volumn 26, Issue 18, 2012, Pages 2399-2403

  Thirumurthy, Harsha ^a   Siripong, Nalyn ^a   Vreeman, Rachel C ^b   Pop Eleches, Cristian ^c   Habyarimana, James P ^d   Sidle, John E ^b   Siika, Abraham M ^e   Bangsberg, David R ^f,g,h  

^a IL   (United States)

^b INDIANA UNIVERSITY   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d GEORGETOWN UNIVERSITY LAW CENTER   (United States)

^e MOI UNIVERSITY   (Kenya)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

^h MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

adherence; adherence measurement, antiretroviral therapy; electronic monitoring

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; MEDICATION EVENT MONITORING SYSTEM CAP; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DRUG MONITORING; DRUG PACKAGING; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KENYA; MAJOR CLINICAL STUDY; MALE; MEDICATION EVENT MONITORING SYSTEM; MOBILE PHONE; PATIENT COMPLIANCE; PATIENT MONITORING; PILL; PRIORITY JOURNAL; SELF REPORT;

ADULT; ELECTRICAL EQUIPMENT AND SUPPLIES; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; KENYA; MALE; MEDICATION ADHERENCE; MONITORING, AMBULATORY; QUESTIONNAIRES; SELF DISCLOSURE; VIRAL LOAD;

EID: 84870238335     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328359aa68     Document Type: Article

References (18)

1. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30. (Pubitemid 30432540)
2. Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000;14:357-366. (Pubitemid 30182431)
3. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy? AIDS 2003;17:711-720. (Pubitemid 36521077)
4. Ware NC, Idoko J, Kaaya S, Biraro IA, Wyatt MA, Agbaji O, et al. Explaining adherence success in sub-Saharan Africa: an ethnographic study. PLoS Med 2009;6:e11.
5. Tuller DM, Bangsberg DR, Senkungu J, Ware NC, Emenyonu N, Weiser SD. Transportation costs impede sustained adherence and access to HAART in a clinic population in southwestern Uganda: a qualitative study. AIDS Behav 2010;14:778-784.
6. Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, Wu P, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med 2006;3:e438.
7. Ajose O, Mookerjee S, Mills EJ, Boulle A, Ford N. Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. AIDS 2012;26:929-938.
8. Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, Singh S, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 2006;296:679-690. (Pubitemid 44200639)
9. Liu H, Golin CE, Miller LG, Hays RD, Beck CK, Sanandaji S, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001;134:968-977. (Pubitemid 32466236)
10. Hinkin CH, Hardy DJ, Mason KI, Castellon SA, Durvasula RS, Lam MN, et al. Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS 2004;18(Suppl 1):S19-25. (Pubitemid 38365902)
11. Levine AJ, Hinkin CH, Castellon SA, Mason KI, Lam MN, Perkins A, et al. Variations in patterns of highly active antiretroviral therapy (HAART) adherence. AIDS Behav 2005;9:355-362. (Pubitemid 41584987)
12. Oyugi JH, Byakika-Tusiime J, Charlebois ED, Kityo C, Mugerwa R, Mugyenyi P, et al. Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr 2004;36:1100-1102. (Pubitemid 38989377)
13. Pop-Eleches C, Thirumurthy H, Habyarimana JP, Zivin JG, Goldstein MP, de Walque D, et al. Mobile phone technologies improve adherence to antiretroviral treatment in a resourcelimited setting: a randomized controlled trial of text message reminders. AIDS 2011;25:825-834.
14. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006;43:939-941. (Pubitemid 44435526)
15. Bangsberg D, Hecht F, Charlebois E, Chesney M, Moss A. Comparing objective measures of adherence to HIV antiretroviral therapy: electronic medication monitors and unannounced pill counts. AIDS Behav 2001;5:275-281. (Pubitemid 35364540)
16. Arnsten JH, Demas PA, Farzadegan H, Grant RW, Gourevitch MN, Chang CJ, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis 2001;33:1417-1423. (Pubitemid 32955198)
17. Byakika-Tusiime J, Crane J, Oyugi JH, Ragland K, Kawuma A, Musoke P, et al. Longitudinal antiretroviral adherence in HIVR Ugandan parents and their children initiating HAART in the MTCT-Plus family treatmentmodel: role of depression in declining adherence over time. AIDS Behav 2009;13(Suppl 1):82-91.
18. Bisson GP, Gross R, Bellamy S, Chittams J, Hislop M, Regensberg L, et al. Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. PLoS Med 2008;5:e109.